At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
Cipherome Lighthouse Pilotother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics: the Lighthouse Pilot (Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects)
In Brief
A clinical study evaluating Cipherome Lighthouse Pilot for Thrombosis and 4 related conditions. Completed, enrolled 300 participants across 1 site.
Detailed Summary
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of toxicity of a therapeutic regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
CountriesUnited States
CollaboratorsDHR Health Institute for Research and Development
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedJan 2021
Primary CompletionJul 2023
Study CompletionJul 2023
TodayJul 2026
First PostedJan 8, 2021
Enrollment StartDec 3, 2020
Primary CompletionJul 26, 2023
Study CompletionJul 27, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.5 years ago
Interventions
Cipherome Lighthouse Pilotother
Preemptive pharmacogenomic testing